Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in alzheimer's disease

Current Alzheimer Research

Volumn 9, Issue 1, 2012, Pages 99-109

  Tobinick, Edward ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Cerebrospinal; Csf contacting; Dementia; Etanercept; Perispinal; Tanycytes; Tnf

Indexed keywords

AMPA RECEPTOR; ETANERCEPT; PLACEBO; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; ARTICLE; ATTENTION; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; COGNITION; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; HUMAN; MEMORY; MOOD; MOTOR PERFORMANCE; NERVE CELL NETWORK; NONHUMAN; PARENCHYMA; PHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TANYCYTE;

EID: 84856459784     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512799015073     Document Type: Article

References (152)

1. Kuhn TS. The Structure of Scientific Revolutions (The University of Chicago Press., 1962).
2. Wolinsky H. Paths to acceptance. The advancement of scientific knowledge is an uphill struggle against 'accepted wisdom'. EMBO Rep 9(5): 416-418 (2008).
3. Ellis H. Ignaz Semmelweis: tragic pioneer in the prevention of puerperal sepsis. Br J Hosp Med (Lond) 69(6): 358 (2008).
4. Lang L. Barry Marshall 2005 Nobel laureate in medicine and physiology. Gastroenterology 129(6): 1813-1814 (2005).
5. Sobel RK. Barry Marshall. A gutsy gulp changes medical science. US News World Rep 131(7): 59 (2001).
6. Sheridan C. J&J's billion dollar punt on anti-amyloid antibody. Nat Biotechnol 27(8): 679-681 (2009).
7. Smith MA, Atwood CS, Joseph JA, Perry G. Predicting the failure of amyloid-beta vaccine. Lancet 359(9320): 1864-1865 (2002).
8. Soscia SJ, Kirby JE, Washicosky KJ, et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5(3): e9505 (2010).
9. Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci 1019: 1-4 (2004).
10. Joseph J, Shukitt-Hale B, Denisova NA, Martin A, Perry G, Smith MA. Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol Aging 22(1): 131-146 (2001).
11. Maarouf C, Daugs I, Kokjohn T, et al. The biochemical aftermath of anti-amyloid immunotherapy. Mol Neurodegener 5: 39 (2010).
12. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634): 216-223 (2008).
13. Wilcock GK. Bapineuzumab in Alzheimer's disease: where now? Lancet Neurol 9(2): 134-136 (2010).
14. Vellas B. Tarenflurbil for Alzheimer's disease: a shot on goal that missed. Lancet Neurol 9(3): 235-237 (2010).
15. Talan J. New study theorizes that amyloid beta protein is an antimicrobial peptide: a shift in the thinking about Alzheimer disease? Neurology Today 10(9): 22 (2010).
16. Robinson SR, Bishop GM, Lee HG, Munch G. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 25(5): 609-615 (2004).
17. Boche D, Denham N, Holmes C, Nicoll JA. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120(3): 369-384 (2010).
18. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73(24): 2061-2070 (2009).
19. Alvarez V, Mata IF, Gonzalez P, et al. Association between the TNFalpha-308 A/G polymorphism and the onset-age of Alzheimer disease. Am J Med Genet 114(5): 574-577 (2002).
20. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 31(11): 1877-1884 (2010).
21. Di Bona D, Candore G, Franceschi C, et al. Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. Brain Res Rev 61(2): 60-68 (2009).
22. Giuliani F, Vernay A, Leuba G, Schenk F. Decreased behavioral impairments in an Alzheimer mice model by interfering with TNFalpha metabolism. Brain Res Bull 80(4-5): 302-308 (2009).
23. Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation 5: 3 (2008).
24. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73(10): 768-774 (2009).
25. Hu NW, Klyubin I, Anwy R, Rowan MJ. GluN2B subunitcontaining NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci USA 106(48): 20504-20509 (2009).
26. Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation 2: 23 (2005).
27. Janelsins MC, Mastrangelo MA, Park KM, et al. Chronic neuronspecific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol 173(6): 1768-1782 (2008).
28. Laws SM, Perneczky R, Wagenpfeil S, et al. TNF polymorphisms in Alzheimer disease and functional implications on CSF betaamyloid levels. Hum Mutat 26(1): 29-35 (2005).
29. Lio D, Annoni G, Licastro F, et al. Tumor necrosis factor-alpha - 308A/G polymorphism is associated with age at onset of Alzheimer's disease. Mech Ageing Dev 127(6): 567-571 (2006).
30. McAlpine FE, Lee JK, Harms AS, et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents preplaque amyloid-associated neuropathology. Neurobiol Dis 34(1): 163-177 (2009).
31. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5: 45 (2008).
32. McNaull BB, Todd S, McGuinness B, Passmore AP. Inflammation and anti-inflammatory strategies for Alzheimer's disease--a minireview. Gerontology 56(1): 3-14 (2010).
33. Medeiros R, Figueiredo CP, Pandolfo P, et al. The role of TNFalpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Behav Brain Res 209(1): 165-173 (2010).
34. Medeiros R, Prediger RD, Passos GF, et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 27(20): 5394-5404 (2007).
35. Park KM, Bowers WJ. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 22(7): 977-983 (2010).
36. Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 22(6): 873-883 (2001).
37. Ramos EM, Lin MT, Larson EB, et al. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of lateonset Alzheimer disease. Arch Neurol 63(8): 1165-1169 (2006).
38. Rogers J. The inflammatory response in Alzheimer's disease. J Periodontol 79(8): 1535-1543 (2008).
39. Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptideinduced dysfunction. Biochem Soc Trans 35(5): 1219-1223 (2007).
40. Sarajarvi T, Helisalmi S, Antikainen L, et al. An association study of 21 potential Alzheimer's disease risk genes in a Finnish population. J Alzheimers Dis 21(3): 763-767 (2010).
41. Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 68(22): 1902-1908 (2007).
42. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 74(9): 1200-1205 (2003).
43. Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 19(4): 223-230 (1999).
44. Teeling JL, Perry VH. Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience 158(3): 1062-1073 (2009).
45. Tobinick E. Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res 4(5): 550-552 (2007).
46. Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence. CNS Drugs 23(9): 713-725 (2009).
47. Tobinick E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today 14(3-4): 168-177 (2009).
48. Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Review of Neurotherapeutics 10(6): 985-1002 (2010).
49. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 8(2): 25 (2006).
50. Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol 8: 27 (2008).
51. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 5: 2 (2008).
52. Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res 4(4): 378-385 (2007).
53. Van Eldik LJ, Thompson WL, Ralay Ranaivo H, Behanna HA, Martin Watterson D. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: functionbased and target-based discovery approaches. Int Rev Neurobiol 82: 277-296 (2007).
54. Wang Y. P4-266: Modification of synaptic plasticity by TNF and sphingomyelinase: Implications for cognitive impairment in Alzheimer's disease. Alzheimers Dement 4(4): T749 (2008).
55. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 33(3): 355-366 (2009).
56. Tobinick E. Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape J Med 10(6): 135 (2008).
57. Ferguson AR, Christensen RN, Gensel JC, et al. Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane. J Neurosci 28(44): 11391-11400 (2008).
58. Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs 25(2): 145-155 (2011).
59. Tobinick E, Vega CP. The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed 8(1): 53 (2006).
60. Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes 2: 28 (2009).
61. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther 128(3): 519-548 (2010).
62. Wang Q, Wu J, Rowan MJ, Anwyl R. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 22(11), 2827-2832 (2005).
63. O'Bryant SE, Xiao G, Barber R, et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67(9): 1077-1081 (2010).
64. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13(11): 1359-1362 (2007).
65. Chen YM, Chen HH, Lan JL, Chen DY. Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis. Joint Bone Spine 77(4): 366-367 (2010).
66. Chio CC, Lin JW, Chang MW, et al. Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem 115(4): 921-929 (2010).
67. Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M. Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 80(3): 212-219 (2010).
68. Alkam T, Nitta A, Mizoguchi H, et al. Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res, 189(1), 100-106 (2008).
69. Gorlovoy P, Larionov S, Pham TT, Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB J 23(8): 2502-2513 (2009).
70. Minami SS, Sidahmed E, Aid S, et al. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Abeta/amyloid burden in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 7(1): 57 (2010).
71. Perry VH. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol 120(3): 277-286 (2010).
72. Shi J, Shen W, Chen J, et al. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cells in the APP/PS1 transgenic mouse brain. Brain Research 1368: 239-247 (2011).
73. Frankola KA, Greig NH, Luo W, Tweedie D. Targeting TNFAlpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. CNS Neurol Disord Drug Targets [Epub ahead of print] (2011).
74. Banks WA, Plotkin SR, Kastin AJ. Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation 2(3): 161-165 (1995).
75. Veening JG, Barendregt HP. The regulation of brain states by neuroactive substances distributed via the cerebrospinal fluid; a review. Cerebrospinal Fluid Res 7: 1 (2010a).
76. Veening JG, de Jong T, Barendregt HP. Oxytocin-messages via the cerebrospinal fluid: behavioral effects; a review. Physiol Behav 101(2): 193-210 (2010).
77. Vizi ES, Fekete A, Karoly R, Mike A. Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment. Br J Pharmacol 160(4): 785-809 (2010).
78. Strakowski SM, DelBello MP, Zimmerman ME, et al. Ventricular and periventricular structural volumes in first- versus multipleepisode bipolar disorder. Am J Psychiatry 159(11): 1841-1847 (2002).
79. Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 40(5): 385-403 (2010).
80. Potschka H. Targeting the brain--surmounting or bypassing the blood-brain barrier. Handb Exp Pharmacol (197): 411-431 (2010).
81. Johanson CE, Duncan JA, Stopa EG, Baird A. Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 22(7): 1011-1037 (2005).
82. Johanson CE, Duncan JA, 3rd, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res 5: 10 (2008).
83. Konsman JP, Tridon V, Dantzer R. Diffusion and action of intracerebroventricularly injected interleukin-1 in the CNS. Neuroscience 101(4): 957-967 (2000).
84. Proescholdt MG, Chakravarty S, Foster JA, Foti SB, Briley EM, Herkenham M. Intracerebroventricular but not intravenous interleukin-1beta induces widespread vascular-mediated leukocyte infiltration and immune signal mRNA expression followed by brain-wide glial activation. Neuroscience 112(3): 731-749 (2002).
85. Proescholdt MG, Hutto B, Brady LS, Herkenham M. Studies of cerebrospinal fluid flow and penetration into brain following lateral ventricle and cisterna magna injections of the tracer [14C]inulin in rat. Neuroscience 95(2): 577-592 (2000).
86. Zheng W, Chodobski A. The blood-cerebrospinal fluid barrier (Chapman & Hall/CRC, 2005).
87. Bruni JE. Ependymal development, proliferation, and functions: a review. Microsc Res Tech 41(1): 2-13 (1998).
88. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101(2): 466-468 (2003).
89. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25(11): 1350-1356 (2007).
90. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 15(1): 129-133 (2004).
91. Banks WA. Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain? Curr Pharm Des 10(12): 1365-1370 (2004).
92. Bohac D, Burke W, Cotter R, Zheng J, Potter J, Gendelman H. A 24-week randomized, double-blind, placebo-controlled study of the efficacy and tolerability of TNFR: Fc (etanercept) in the treatment of dementia of the Alzheimer type. Neurobiol Aging 23(S1): 315 (2002).
93. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull 61(3): 255-260 (2003).
94. Kang YM, He RL, Yang LM, et al. Brain tumour necrosis factoralpha modulates neurotransmitters in hypothalamic paraventricular nucleus in heart failure. Cardiovasc Res 83(4): 737-746 (2009).
95. Tobinick EL, Britschgi-Davoodifar S. Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly 133(11-12): 170-177 (2003).
96. Tobinick E, Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin 20(7): 1075-1085 (2004).
97. Tobinick EL. Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther 25(8): 2279-2288 (2003).
98. Tobinick EL. Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clin Ther 25(4): 1211-1218 (2003).
99. Batson OV. The vertebral vein system. Caldwell lecture, 1956. Am J Roentgenol Radium Ther Nucl Med 78(2): 195-212 (1957).
100. Batson OV. The function of the vertebral veins and their role in the spread of metastases. 1940. Clin Orthop Relat Res (312): 4-9 (1995).
101. Groen RJ, du Toit DF, Phillips FM, et al. Anatomical and pathological considerations in percutaneous vertebroplasty and kyphoplasty: a reappraisal of the vertebral venous system. Spine 29(13): 1465-1471 (2004).
102. Groen RJ, Groenewegen HJ, van Alphen HA, Hoogland PV. Morphology of the human internal vertebral venous plexus: a cadaver study after intravenous Araldite CY 221 injection. Anat Rec 249(2): 285-294 (1997).
103. Cohen SP, Bogduk N, Dragovich A, et al. Randomized, doubleblind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology 110(5): 1116-1126 (2009).
104. Vigh B, Manzano e Silva MJ, Frank CL, et al. The system of cerebrospinal fluid-contacting neurons. Its supposed role in the nonsynaptic signal transmission of the brain. Histol Histopathol 19(2): 607-628 (2004).
105. Vigh-Teichmann I, Vigh B. The system of cerebrospinal fluidcontacting neurons. Arch Histol Jpn 46(4): 427-468 (1983).
106. De Rotte AA, Bouman HJ, van Wimersma Greidanus TB. Relationships between alpha-MSH levels in blood and in cerebrospinal fluid. Brain Res Bull 5(4): 375-381 (1980).
107. Vigh B, Vigh-Teichmann I. Actual problems of the cerebrospinal fluid-contacting neurons. Microsc Res Tech 41(1): 57-83 (1998).
108. Vigh B, Vigh-Teichmann I, Manzano e Silva MJ, van den Pol AN. Cerebrospinal fluid-contacting neurons of the central canal and terminal ventricle in various vertebrates. Cell Tissue Res 231(3): 615-621 (1983).
109. Vigh-Teichmann I, Vigh B. The cerebrospinal fluid-contacting neuron: a peculiar cell type of the central nervous system. Immunocytochemical aspects. Arch Histol Cytol 52(S): 195-207 (1989).
110. Mitchell JA. Scanning electron microscopy of brain ventricular surfaces: a bibliography. Scan Electron Microsc 3: 474-484 (1980).
111. Sano Y, Ueda S, Yamada H, Takeuchi Y, Goto M, Kawata M. Immunohistochemical demonstration of serotonin-containing CSFcontacting neurons in the submammalian paraventricular organ. Histochemistry 77(4): 423-430 (1983).
112. Xiao M, Ding J, Wu L, et al. The distribution of neural nitric oxide synthase-positive cerebrospinal fluid-contacting neurons in the third ventricular wall of male rats and coexistence with vasopressin or oxytocin. Brain Res 1038(2): 150-162 (2005).
113. Zhang LC, Zeng YM, Ting J, Cao JP, Wang MS. The distributions and signaling directions of the cerebrospinal fluid contacting neurons in the parenchyma of a rat brain. Brain Res 989(1): 1-8 (2003).
114. Stoeckel ME, Uhl-Bronner S, Hugel S, et al. Cerebrospinal fluidcontacting neurons in the rat spinal cord, a gamma-aminobutyric acidergic system expressing the P2X2 subunit of purinergic receptors, PSA-NCAM, and GAP-43 immunoreactivities: light and electron microscopic study. J Comp Neurol 457(2): 159-174 (2003).
115. Vigh B, Vigh-Teichmann I. Cytochemistry of CSF-contacting neurons and pinealocytes. Prog Brain Res 91: 299-306 (1992).
116. Blahser S, Vigh-Teichmann I, Ueck M. Cerebrospinal fluidcontacting neurons and other somatostatin-immunoreactive perikarya in brains of tadpoles of Xenopus laevis. Cell Tissue Res 224(3): 693-697 (1982).
117. Melendez-Ferro M, Perez-Costas E, Villar-Cheda B, et al. Ontogeny of gamma-aminobutyric acid-immunoreactive neuronal populations in the forebrain and midbrain of the sea lamprey. J Comp Neurol 446(4): 360-376 (2002).
118. Vigh B, Vigh-Teichmann I, Aros B. Special dendritic and axonal endings formed by the cerebrospinal fluid contacting neurons of the spinal cord. Cell Tissue Res 183(4)541-552 (1977).
119. Wilson KH. The genome sequence of the protostome Daphnia pulex encodes respective orthologues of a neurotrophin, a Trk and a p75NTR: evolution of neurotrophin signaling components and related proteins in the bilateria. BMC Evol Biol 9: 243 (2009).
120. Yuan S, Liu T, Huang S, et al. Genomic and functional uniqueness of the TNF receptor-associated factor gene family in amphioxus, the basal chordate. J Immunol 183(7): 4560-4568 (2009).
121. Babcock DT, Landry C, Galko MJ. Cytokine signaling mediates UV-induced nociceptive sensitization in Drosophila larvae. Curr Biol 19(10): 799-806 (2009).
122. Nadeau S, Rivest S. Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience 93(4): 1449-1464 (1999).
123. Peruzzo B, Pastor FE, Blazquez JL, et al. A second look at the barriers of the medial basal hypothalamus. Exp Brain Res 132(1): 10-26 (2000).
124. Sanchez E, Singru PS, Wittmann G, et al. Contribution of TNFalpha and nuclear factor-kappaB signaling to type 2 iodothyronine deiodinase activation in the mediobasal hypothalamus after lipopolysaccharide administration. Endocrinology 151(8): 3827-3835 (2010).
125. Akmayev IG, Popov AP. Morphological aspects of the hypothalamic-hypophyseal system. VII. The tanycytes: Their relation to the hypophyseal adrenocorticotrophic function. An ultrastructural study. Cell Tissue Res 180(2): 263-282 (1977).
126. Bruni JE, Clattenburg RE, Millar E. Tanycyte ependymal cells in the third ventricle of young and adult rats: a Golgi study. Anat Anz 153(1): 53-68 (1983).
127. Rodriguez EM, Blazquez JL, Pastor FE, et al. Hypothalamic tanycytes: a key component of brain-endocrine interaction. Int Rev Cytol 247: 89-164 (2005).
128. Sharp PJ. Tanycyte and vascular patterns in the basal hypothalamus of Coturnix quail with reference to their possible neuroendocrine significance. Z Zellforsch Mikrosk Anat 127(4): 552-569 (1972).
129. Wagner HJ, Pilgrim C. Extracellular and transcellular transport of horseradish peroxidase (HRP) through the hypothalamic tanycyte ependyma. Cell Tissue Res 152(4): 477-491 (1974).
130. Horstmann E. Die Faserlia des Selachiergehirns. Z. Zellforsch, 39: 588-617 (1954).
131. Pilgrim C. Transport function of hypothalamic tanycyte ependyma: how good is the evidence? Neuroscience 3(3): 277-283 (1978).
132. Beattie EC, Stellwagen D, Morishita W, et al. Control of synaptic strength by glial TNFalpha. Science 295(5563): 2282-2285 (2002).
133. Beattie MS, Ferguson AR, Bresnahan JC. AMPA-receptor trafficking and injury-induced cell death. Eur J Neurosci 32(2): 290-7 (2010).
134. Stellwagen D, Beattie EC, Seo JY, Malenka RC. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 25(12): 3219-3228 (2005).
135. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature 440(7087): 1054-1059 (2006).
136. Tancredi V, D'Arcangelo G, Grassi F, et al. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett 146(2): 176-178 (1992).
137. Fields RD, Burnstock G. Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci 7(6): 423-436 (2006).
138. Fields RD, Stevens B. ATP: an extracellular signaling molecule between neurons and glia. Trends Neurosci 23(12): 625-633 (2000).
139. Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 13(2): 54-63 (2007).
140. Halassa MM, Fellin T, Haydon PG. Tripartite synapses: roles for astrocytic purines in the control of synaptic physiology and behavior. Neuropharmacology 57(4): 343-346 (2009).
141. Oliet SH, Piet R, Poulain DA, Theodosis DT. Glial modulation of synaptic transmission: Insights from the supraoptic nucleus of the hypothalamus. Glia 47(3): 258-267 (2004).
142. Wieronska JM, Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int 55(1-3): 85-97 (2009).
143. Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 32(8): 421-431 (2009).
144. Bains JS, Oliet SH. Glia: they make your memories stick! Trends Neurosci 30(8): 417-424 (2007).
145. 2+-dependent modulation of GABAA and NMDA receptors by extracellular ATP: implication for function of tripartite synapse. Biochem Soc Trans, 37(Pt 6): 1407-1411 (2009).
146. Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 15(5): 525-539 (2009).
147. Bushong EA, Martone ME, Jones YZ, Ellisman MH. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J Neurosci 22(1): 183-192 (2002).
148. DeFelipe J, Farinas I. The pyramidal neuron of the cerebral cortex: morphological and chemical characteristics of the synaptic inputs. Prog Neurobiol 39(6): 563-607 (1992).
149. Houweling AR, Brecht M. Behavioural report of single neuron stimulation in somatosensory cortex. Nature 451(7174): 65-68 (2008).
150. Bullock TH, Bennett MV, Johnston D, Josephson R, Marder E, Fields RD. Neuroscience. The neuron doctrine, redux. Science 310(5749): 791-793 (2005).
151. Lopez-Munoz F, Boya J, Alamo C. Neuron theory, the cornerstone of neuroscience, on the centenary of the Nobel Prize award to Santiago Ramon y Cajal. Brain Res Bull 70(4-6): 391-405 (2006).
152. Gottlieb AB, Gordon K, Giannini EH, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 10(3): 289-300 (2011).